Skip to main content
. 2022 Feb 12;11(4):e024159. doi: 10.1161/JAHA.121.024159

Table 1.

Patient Characteristics at the Time of Index PCI

Characteristic All patients (n=3342) LOF‐alternative (n=571) LOF‐clopidogrel (n=461) Standardized differences for comparison of LOF‐alternative vs LOF‐clopidogrel Non‐LOF‐alternative (n=378) Non‐LOF‐clopidogrel (n=1932) Standardized differences for comparison of non‐LOF alternative vs non‐LOF‐clopidogrel
Age, y 63±12 60±11 64±12 0.336 60±10 64±12 0.349
Female sex 1075 (32) 158 (28) 161 (35) 0.157 99 (26) 657 (34) 0.171
Race
White 2448 (73) 413 (72) 315 (68) 0.088 287 (76) 1433 (74) 0.08
Black 659 (20) 117 (21) 109 (24) 62 (16) 371 (19)
Other 235 (7) 41 (7) 37 (8) 29 (8) 128 (7)
BMI, kg/m2 30±6 30±7 30±7 0.054 31±6 30±6 0.14
Current smoker 969 (29) 178 (31) 138 (30) 0.027 114 (30) 539 (28) 0.05
PCI indication
ACS 2290 (69) 412 (72) 306 (66) 0.125* 290 (77) 1282 (66) 0.231*
STEMI 628 (19) 148 (26) 53 (12) 106 (28) 321 (17)
NSTEMI 939 (28) 161 (28) 134 (29) 117 (31) 527 (27)
Unstable angina 723 (22) 103 (18) 119 (26) 67 (18) 434 (23)
Stable CAD 936 (28) 143 (25) 137 (30) 80 (21) 576 (30)
Other/unknown 116 (4) 16 (3) 18 (4) 8 (2) 74 (4)
PCI type
Drug‐eluting stent 2868 (86) 485 (85) 388 (84) 0.021 348 (92) 1647 (85) 0.216
Bare metal stent 371 (11) 65 (11) 48 (10) 0.031 25 (7) 233 (12) 0.188
PTCA 85 (3) 16 (3) 20 (4) 0.083 4 (1) 45 (2) 0.099
Medical history
Diabetes 1354 (41) 190 (33) 206 (45) 0.236 130 (34) 828 (43) 0.175
Hypertension 2704 (81) 428 (75) 389 (84) 0.236 286 (76) 1601 (83) 0.178
Dyslipidemia 2317 (69) 394 (69) 329 (71) 0.052 244 (65) 1350 (70) 0.114
CKD 963 (29) 161 (28) 165 (36) 0.163 59 (16) 578 (30) 0.346
MI 866 (26) 142 (25) 136 (30) 0.104 97 (26) 491 (25) 0.006
Coronary stent 770 (23) 113 (20) 117 (25) 0.134 83 (22) 457 (24) 0.04
Stroke/TIA 348 (10) 41 (7) 70 (15) 0.256 16 (4) 221 (11) 0.271
PVD 335 (10) 49 (9) 66 (14) 0.181 19 (5) 201 (10) 0.203
Heart failure 533 (16) 78 (14) 89 (19) 0.153 38 (10) 328 (17) 0.204
Atrial fibrillation 316 (10) 40 (7) 55 (12) 0.169 15 (4) 206 (11) 0.259
Gastrointestinal or intracranial hemorrhage 111 (3) 20 (4) 26 (6) 0.102 7 (2) 58 (3) 0.075
Cancer 184 (6) 26 (5) 22 (5) 0.01 14 (4) 122 (6) 0.12
Discharge medication
Aspirin 3269 (98) 563 (99) 449 (97) 0.086 371 (98) 1886 (98) 0.037
Statin 3143 (94) 548 (96) 434 (94) 0.084 365 (97) 1796 (93) 0.162
ACE inhibitor or ARB 2245 (67) 400 (70) 306 (66) 0.079 251 (66) 1288 (67) 0.006
β‐blocker 2852 (85) 483 (85) 378 (82) 0.07 325 (86) 1666 (86) 0.007
Anticoagulant 321 (10) 36 (6) 55 (12) 0.196 21 (6) 209 (11) 0.193

Data are presented as number (%) or mean±SD. LOF‐clopidogrel patients were those with at least 1 loss‐of‐function allele (ie, *2, *3…) treated with clopidogrel. LOF‐alternative patients were those with at least 1 loss‐of‐function allele (ie, *2, *3…) treated with prasugrel, ticagrelor, or high dose clopidogrel. Non‐LOF patients were those with no loss‐of‐function allele: *1/*1, *1/*17, or *17/*17 genotype. ACE indicates angiotensin‐converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease defined as an estimated glomerular filtration rate of <60 mL/min per 1.73 m2; MI, myocardial infarction; LOF, loss‐of‐function; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; PVD, peripheral vascular disease; STEMI, ST‐segment elevation myocardial infarction; and TIA, transient ischemic attack.

*

Standardized difference for comparison of primary PCI indication categories (ie, ACS vs stable CAD or other) between groups.

Indicates patients who self‐identify as American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander, or more than one race, and patients with unknown race in the electronic health record.